Prevention of in Vivo Excitotoxicity by a Family of Trialkylglycines, a Novel Class of Neuroprotectants
Authors:
- Marc HumetMHMarc Humet
- Juan-José CanalesJCJuan-José Canales
- Jozef BurdaJBJozef Burda
- Rosa Planells-CasesRPRosa Planells-Cases
- Francisco Sánchez-BaezaFSFrancisco Sánchez-Baeza
- Teresa CarbonellTCTeresa Carbonell
- Enrique Pérez-PayáEPEnrique Pérez-Payá
- Angel MesseguerAMAngel Messeguer
- Antonio Ferrer-MontielAFAntonio Ferrer-Montiel
- Vicente FelipoVicente Felipo
- 1 April 2002
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 301 (1) , 29-36
Abstract
Excitotoxicity has been implicated in the etiology of ischemic stroke and chronic neurodegenerative disorders. Hence, the development of novel neuroprotectant molecules that ameliorate excitotoxic brain damage is vigorously pursued. We used a neuroprotection-based cellular assay to screen a synthetic combinatorial library ofN-alkylglycine trimers. Two compounds (6-1-2 and 6-1-10) that efficiently prevented excitotoxic neurodegeneration in vitro and in vivo were identified. Both molecules protected primary cultures of cerebellar neurons against glutamate-induced neuronal death with an efficiency equivalent toN-methyl-d-aspartate (NMDA) receptor antagonists. These trialkylglycines did not block appreciably the NMDA receptor channel, or attenuated glutamate-induced increase of Ca2+, or affect the glutamate-nitric oxide-cGMP pathway. Intraperitoneal injection of both peptoids in mice attenuated ≥80% ammonia-induced, NMDA receptor-mediated animal death. Furthermore, these two molecules reduced by ≥50% the neurodegeneration in striatum in a rat model of cerebral ischemia. Neuroprotection against ischemia was associated with decreased activation of caspase-3, reflecting prevention of apoptotic neuronal death. Collectively, the results reported indicate that these trialkylglycines are new neuroprotectant leads with important in vivo activity against excitotoxicity, and that they act on a novel, yet-unrecognized cellular target. These lead compounds may become tolerated drugs for the treatment of acute and chronic neurodegenerative diseases with fewer side effects than NMDA receptor antagonists.Keywords
This publication has 33 references indexed in Scilit:
- Activation of N -methyl-d-aspartate receptors in rat brain in vivo following acute ammonia intoxication: Characterization by in vivo brain microdialysisHepatology, 2000
- An Oral Vaccine Against NMDAR1 with Efficacy in Experimental Stroke and EpilepsyScience, 2000
- Nicotine prevents glutamate-induced proteolysis of the microtubule-associated protein MAP-2 and glutamate neurotoxicity in primary cultures of cerebellar neuronsNeuropharmacology, 1998
- Selected peptides targeted to the NMDA receptor channel protect neurons from excitotoxic deathNature Biotechnology, 1998
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settingsAdvanced Drug Delivery Reviews, 1997
- Nitric oxide, superoxide and peroxynitrite: Putative mediators of NMDA-induced cell death in cerebellar granule cellsNeuropharmacology, 1993
- Growth Factors Prevent Mitochondrial Dysfunction, Loss of Calcium Homeostasis, and Cell Injury, but Not ATP Depletion in Hippocampal Neurons Deprived of GlucoseExperimental Neurology, 1993
- Acute ammonia toxicity is mediated by the NMDA type of glutamate receptorsFEBS Letters, 1992
- A modified four-vessel occlusion model for inducing incomplete forebrain ischemia in rats.Stroke, 1989
- A new model of bilateral hemispheric ischemia in the unanesthetized rat.Stroke, 1979